Skip to main content
. Author manuscript; available in PMC: 2023 Mar 2.
Published in final edited form as: Mol Cancer Res. 2022 Sep 2;20(9):1429–1442. doi: 10.1158/1541-7786.MCR-22-0085

Figure 4: Downregulation of VDAC reduces the effect of CERK inhibition/downregulation on Mut KRAS NSCLC cell survival and MMP.

Figure 4:

(A-C) A549/H838 cells (both LUAD-derived) transfected with control/VDAC1 siRNA (siCon or siVD1) for 48h were subjected to SDS-PAGE/immunoblotting (A) or treated with NVP 231 [(0-400 nM) in (B), 400 nM on (C)]; 24 hour-post-NVP treatment, cells were utilized in clonogenic cell survival assay (B) or MMP assay (C). (D-F) Clonogenic cell survival assay (D), MMP assay (E) or Western immunoblotting (F) was performed from cells transfected with siCon or siVD1 for 24 hours then with control (siCon) or CERK (siCE) siRNA for additional 48 hours. (G) RT-qPCR was utilized from RNA samples prepared from cells transfected with siCon or siCE for 72 hours. Data in graphs are means ± SD; n = 4-6 from at least two independent occasions. *p<0.01, **p<0.0001, ***p<0.00001. Scale bar = 200 μm. Unless otherwise noted by an * or depicted p-value, data are not significant between depicted groups; p>0.05.